This study concluded that a modest number of BC patients were suitable for PSMA-targeted RLT and that PSMA-targeted PET/CT imaging could be beneficial for BC patients as a “theranostics selector” in a subset of BC patients, particularly those with TN and hormone receptor-negative/HER2+ hormonal statuses for PSMA-targeting RLT. The gene discussed is FOLH1; the disease is breast cancer.